Now Live: Public Preview

What the public preview means

Ligant.ai is live and open to everyone. The public preview is the real platform, free to start, while we finalize the production release. Here is exactly what that means for you.

What is the public preview?

It is full, self-serve access to the Ligant.ai platform while we harden it toward a production release. The agents, the evidence pipeline, and the data foundations are all live. There is no application and no waitlist. You create an account and start.

What you get

What to expect

The platform is built accuracy-first, but it is early and it is improving every week.

What is in and out of scope

In scope

Adoptive cell therapy: CAR-T, TCR-T, and CAR-NK. Surface-protein target identification, safety triage, competitive and IP landscape, and ranking. CAR-T is our deepest-validated modality.

Out of scope

Gene editing and gene therapy. The agents are not trained to assess targets for those modalities, and will not be able to help with them.

Your data and privacy

What it costs

You start with 500 free credits, enough to get going: frame your hypothesis, generate your hypothesis card, and see the agents’ plan to execute the assessment. How far the credits take you depends on the depth of the work. After that, it is pay-as-you-go with one-time credit packs. No retainer and no minimum. You only pay for what you use.

The road to production

The public preview is a deliberate stage, not a disclaimer. Next on the roadmap are compliance and validation work (SOC 2 and GxP audit trails) in Q3 2026, with a production launch targeted for late 2026.

How to give feedback

We read everything. Your feedback during the preview directly shapes what we build. Reach us anytime through the Contact link on our home page.

Ready to step into the room?

500 free credits. No credit card, no waitlist.

Start free with 500 credits

Or explore the rest of the site.